ANI Pharmaceuticals reports positive phase 4 uveitis trial data
Tweet Send to a Friend
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced results from its SYNCHRONICITY Phase 4 clinical trial evaluating a fluocinolone acetonide intravitreal ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




